Background: Allergic rhinitis (AR) is a common allergic disease. It affects people worldwide and traditional Chinese medicine is becoming popular among AR patients because it has a definite clinical effect and there are few adverse reactions. Lung qi deficiency and cold syndrome (LQDCS) is a frequent type of AR, and the Chinese herbal medicine bimin decoction (BMD) is prescribed for it. This study compared the clinical efficacy of BMD for AR patients with LQDCS to the conventional medicine loratadine and fluticasone nasal spray. Methods: The study was an open-label non-inferiority randomized controlled trial. A total of 108 AR patients with LQDCS aged 19 to 60 were randomly allocated in a 1:1 ratio to the BMD group or the control group by the central computer system in Beijing Hospital of Traditional Chinese Medicine from January 2017 to April 2018. In total, 98 participants completed the study (BMD group n = 51 and control group n = 47). Patients in the BMD group received BMD while those in the control group received fluticasone nasal spray and loratadine tablets for 4 weeks. The primary outcome was the change in the Total Nasal Symptom Score (TNSS) between the baseline and the end of treatment. Changes in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), nasal resistance, and acoustic rhinometry parameters were secondary outcomes. All side effects due to the treatments were recorded. Results: After the 4-week treatment, the total TNSS was significantly reduced in both groups compared to the baseline (P < 0.05). No significant between-groups differences were observed for changes in TNSS scores [− 0.298 (95% confidence interval −0.640 to 0.140)], which was within the defined non-inferiority margin. RQLQ in both groups decreased significantly (P < 0.001) from baseline, though a more obvious reduction was observed for the BMD group (P < 0.001). There were no significant differences in nasal resistance, nasal volume, or nasal minimum cross-sectional area between groups after treatment (P > 0.05). Conclusions: These findings indicate that BMD helps relieve the symptoms of perennial AR and improves rhinitis-related quality of life. Our study indicates that BMD is non-inferior to loratadine tablets and fluticasone nasal spray for AR patients with LQDCS.
Background
Allergic rhinitis (AR) is a common allergic disease, which can be perennial or intermittent [1] . House dust mite is the most important domestic source of AR. Therapy for AR mainly includes avoiding allergens, pharmacotherapy, immunotherapy, and patient education; however, each of these has limitations [2] . The most effective treatment for AR is to avoid exposure to allergens, but airborne allergens are often difficult to avoid. Immunotherapy is not popular among patients due to its long therapy cycle (recommended for 3-5 years) and unsatisfactory results [3] . Therefore, pharmacotherapy is still the main treatment approach for AR. Although antihistamines and intranasal corticosteroids are rapid and accurate in alleviating symptoms, they do not fully regulate a patient's immune status and sometimes have unfavorable side effects [4] . Increasingly patients are turning to complementary and alternative medicines, and thus, traditional Chinese medicine (TCM) has increased in popularity [5] .
A syndrome in TCM covers a series of symptoms. The lung qi deficiency and cold syndrome (LQDCS) is frequently diagnosed for those with perennial allergic rhinitis (PAR). Our department has been treating AR with TCM for several decades and we have empirically formulated the herbal formula bimin decoction (BMD), which is composed of Saposhnikovia divaricata (fangfeng), Astragalus (huangqi), Atractylodes (baizhu), cassia twig (guizhi), radix paeoniae alba (baishao), Prunus mume (wumei), fructus chebulae (hezi), Asarum heterotropoides (xixin), Schisandra chinensis (wuweizi), herba ephedrae (mahuang), and licorice (gancao). BMD contains substances that have been demonstrated to have anti-inflammatory and immune regulation functions [6] [7] [8] [9] , and it is prescribed for AR patients with LQDCS. The current study aimed to compare the clinical efficacy of BMD for PAR patients with LQDCS to the clinical efficacy of the conventional medicines loratadine and fluticasone nasal spray.
Methods

Study design
An open-label non-inferiority randomized controlled trial was carried out to investigate the efficacy of BMD on AR symptoms, quality of life, and nasal resistance (NR) in PAR patients. All participants were recruited from the Otorhinolaryngology Department of Beijing Hospital of Traditional Chinese Medicine (BJHTCM), which is affiliated to Capital Medical University. The study design and protocol were approved by the ethics committee of BJHTCM (code 2016BL-047). The study was conducted in accordance with the principles of the Declaration of Helsinki (2004) and the Medical Research Involving Human Subjects Act. The trial was registered with the China Clinical Trial Registry Center (ChiCTR-INR-16010063) on 2 December 2016. This research will be reported according to the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines [10] .
Participants
Recruitment information was posted in BJHTCM and publicized through the Internet. Participants with PAR who volunteered for the study were selected from January 2017 to April 2018 by physicians at otorhinolaryngology clinics. All participants had to meet the Western medicine diagnostic criteria for AR and the TCM syndrome diagnostic criteria for LQDCS. Syndrome differentiation was separately determined by two independent and qualified TCM otolaryngologists.
Inclusion criteria
Patients had to satisfy all of the following criteria to be included in the trial:
1. Aged 18 to 65 years, male or female 2. Experiencing the symptoms of AR (sneezing, rhinorrhea, itchy nose, and nasal obstruction) for at least 4 days per week for more than 4 weeks [11] , and with a positive skin prick test to house dust mites (+++ or more, ALK reagent) according to the Allergic Rhinitis and its Impact on Asthma criteria (ARIA, 2008) 3. Syndrome differentiation corresponding to LQDCS, which is having a light pink tongue with a thin white coating and a weak pulse [12] 4. Have signed the informed consent form and volunteered to participate in the study 
Exclusion criteria
The following were excluded from participating in the trial:
1. Women who are pregnant or hoping to conceive in the next 6 months, 2. Women who are lactating 3. Those who have nasal polyps, rhinosinusitis, an obvious deviated nasal septum, or upper respiratory tract infection 4. Those who were undergoing treatment for AR 5. Those who have serious disorders such as vascular malformation, hypertension, hematologic 
Randomization and blinding
The physicians were responsible for recruitment and the therapeutic assessment of patients. Participants recruited were randomly allocated into either the BMD group (n = 54) or the control group (n = 54) in a 1:1 ratio by a computer-generated random sequence in the Good Clinical Practice Office of BJHTCM after a 7-day washout period. The physicians did not have access to the sequence. The investigators were responsible for distributing the drugs. All research team members were instructed not to communicate with the participants regarding their allocation. The flow chart is in Fig. 1 and schedule is in Table 1 .
Intervention
All participants completed the Total Nasal Symptom Score (TNSS) questionnaire and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and were assessed for NR and acoustic rhinometry under instruction. The participants in the BMD group received BMD while those in the control group received fluticasone furoate spray (Flixonase, 50 μg × 120 presses, Glaxo Wellcome, S.A.) and loratadine tablets (Clarityne, Shanghai Schering Plough Pharmaceutical Co. Ltd.).
The ingredients in BMD are listed in Table 2 . The herbal medicines used in the study were all produced by Beijing Institute of Traditional Chinese Medicine as a single batch. Each dose was decocted twice. All the herbal materials were soaked in cold water for 1 h before decoction. The first decoction was brought to the boil over a high heat and then simmered at a low heat for 30 min. The liquid was then filtered off. Cold water was added to the herbal materials as the second decoction, which was brought to the boil over high heat and then simmered at a low heat for 15 min. The liquid was filtered off and combined with the liquid from the first decoction to give a total volume of approximately up to 400 ml.
Participants in the BMD group took 200 ml of BMD orally 30 min after breakfast and dinner for 4 weeks. According to the step-up therapy recommended by ARIA [13] , the participants in the control group sprayed two presses per nostril of fluticasone furoate and took a 10 mg tablet of loratadine each night. No other medicines or spicy, fishy, or cold food were allowed during treatment for all participants.
Details were recorded of participants who withdrew or were excluded from the study, and their allocated medication was immediately returned to the investigators. Participants who completed the study were followed up by the physicians and at the end of the treatment period, again completed the TNSS questionnaire and RQLQ and were assessed for NR and acoustic rhinometry. 
Main outcome
The main outcome of this study was the change in TNSS. The measurement was based on four nasal symptoms (sneezing, rhinorrhea, itchy nose, and nasal obstruction). Each was scored from 0 to 3 (0 = none, 1 = mild, 2 = moderate, and 3 = severe).
Secondary outcomes
Qualify of life was assessed with the authorized and Sinicized RQLQ, which has 28 questions on a 7-point scale (0 = not impaired at all to 6 = severely impaired) in 7 domains: (1) activity limitations, (2) sleep problems, (3) nasal symptoms, (4) eye symptoms, (5) non-nose/eye symptoms, (6) practical problems, and (7) emotional functioning [14] . The total score and seven domain scores between groups were compared. All participants rested for 20-30 min and were required to clean up their nasal secretions before being assessed for NR and acoustic rhinometry (model: NR-6, British GM). Bilateral exhalation and inhalation resistance, total NR, and nasal minimum cross-sectional area (NMCA) were recorded. The nasal volume was calculated according to the segment 0-7cm from the anterior nostril. Each patient underwent four measurements on each side and the average was calculated for data analysis.
Sample size
The sample size was evaluated with software SAS 9.3 (SAS Institute Inc., Cary, NC, USA) in the Clinical Evaluation Center of BJHTCM. The mean change in TNSS pre-and posttreatment was set as the indicator in the calculation. From our previous studies, we expected that the mean TNSS change for the BMD group would be 6.62 ± 2.84 and for the control group 5.79 ± 2.18 [15] . For a power of 80%, alpha of 0.05, an acceptable delta of 0.2, and a non-inferiority margin of 0.77 [15] , then a clinically important difference can be detected by a sample size of at least 49 in each group. This number was then increased to 54 in each group (total of 108) to allow for a predicted 10% dropout rate.
Statistical analysis
All statistical analyses were performed using software SPSS (SPSS Inc., Chicago, IL, USA; version 22.0) by qualified statisticians according to the intention-to-treat principle. Descriptive statistics were used to compare baseline measures and patient characteristics between groups. Least-squares mean changes from baseline were Fig. 2 Mean of total nasal symptom score for the 4-week treatment period. Datas were compared with baseline. TNSS, Total Nasal Symptoms Score. BMD, Bimin decoction evaluated using analysis of covariance models for the primary outcome. The two-sample independent t test was used to compare differences in the secondary outcomes. Categorial data were assessed using Fisher's exact test. α = 0.05 was defined as statistically significant.
Results
A total of 108 patients met the criteria and were randomized into the study. Four people were eliminated because they had the common cold and six participants dropped out for personal reasons (Fig. 1 ). There were 51 participants (29 male and 22 female) aged 19 to 60 years (mean 36.8 years, standard deviation 11.6) in the BMD group, and 47 participants (26 male and 21 female) aged 22 to 59 years (mean 37.9 years, standard deviation 10.2) in the control group. There were no significant differences in the demographic characteristics of the groups (Table 3) .
TNSS
The pretreatment TNSS scores were similar in both groups (BMD group 7.84 ± 1.46, control group 8.43 ± 1.56; P = 0.062). After the 4-week treatment, the total TNSS score fell for both groups: for the BMD group from 7.84 ± 1.46 to 2.17 ± 1.26 (P = 0.019) and for the control group from 8.43 ± 1.56 to 2.29 ± 0.93 (P = 0.021) ( Tables 3 and 4 ). The 95% confidence interval for group mean change difference was − 0.640 to 0.140, which is within the defined non-inferiority margin of 0.77 (Table 4 and Fig. 2) .
RQLQ
After the treatment, the single and overall RQLQ scores fell significantly for the two groups: for the BMD group from 67.18 ± 8.19 to 14.54 ± 3.56 (P < 0.001) and for the control group from 66.81 ± 9.23 to 22.45 ± 4.70 (P < 0.001). The fall in RQLQ total score for both groups after treatment was statistically significant (P < 0.001) ( Table 5 ).
Nasal resistance and acoustic rhinometry
There were no significant differences in the change in NR, nasal volume, or NMCA between groups (P > 0.05) ( Tables 6 and 7) .
Safety
Both treatments were well tolerated. Seven patients reported a total of 13 adverse events (BMD group 5, control group 8): dry nose (2), sore throat (2), or sleepiness (1) for the BMD group, and dry nose (4), sore throat (3), or coughing (1) for the control group. None of the adverse events were serious and all were resolved with or without treatment.
Discussion
Modern drug treatments for PAR mainly include antihistamines and intranasal corticosteroids [2] . These medicines have different roles in the prevention and therapy of AR. Although these medications have clear targets, act rapidly, and have pronounced effects, they have different disadvantages to various degrees. For example, intranasal corticosteroids must be used continuously for several days to achieve the maximum effect and then gradually reduced to the minimum dose to control symptoms. However, patients may discontinue treatment when their symptoms appear to be relieved. Antihistamines also have side effects, such as cardiac toxicity, drowsiness, and operational disability [16] . As a result, more and more clinicians and patients are looking for complementary alternative medicines, such as Chinese herbal medicines, to treat AR. TCM treatments not only control the clinical symptoms but also regulate the constitution. AR is a significant disease in TCM, coming under the classification biqiu (鼻鼽). According to TCM, AR is caused by a specific constitutional state, depletion of viscera, and exogenous pathogenic factors. Once the inducing factors have been diagnosed, the symptoms are easy to treat. There is a long history of using TCM to treat AR. TCM can regulate the immune function to relieve symptoms and reduce the frequency of attacks. Research has shown that an ethanolic extract of Asarum heterotropoides (xixin) reduces anaphylaxis, and has antiallergic effects like those of antihistamines [17] . Schisandra chinensis (wuweizi) increases the production of lymphoblastic cells and enhances the immune function. It promotes DNA synthesis by lymphocytes through its lung astringe and kidney nourishment function [18, 19] . Licorice root (gancao) contains glucocorticoids that likely have anti-inflammatory and anti-allergic effects. Its main components are flavonoids and licorice compounds, which may alleviate the cardiac toxicity and side effects of antihistamines [19, 20] .
This study evaluated the efficacy of BMD and indicated that it is non-inferior to antihistamines and intranasal corticosteroids. The differences in changes of TNSS score in the BMD group and the control group after treatment were not statistically significant. The fall in the total RQLQ score after treatment in the BMD group was significantly lower than that of the control group. The obvious improvements relating to sleep, work, and overall comfort indicate the advantages of BMD in improving systemic symptoms. No significant differences in changes of total NR, nasal cavity volume, or NMCA were observed in either group after treatment. We found that BMD alleviates mucosal hyperemia, edema, and nasal turbinate swelling, leading to a reduction of NR and an increase of NMCA. Subsequent research will examine any change in the number of lymphocytes in AR patients after BMD therapy.
Conclusions
This study indicates that BMD is non-inferior to a combination of a fluticasone nasal spray and loratadine in alleviating AR symptoms. Quality of life in the BMD group relating to sleep, work, and overall comfort was significantly better than in the control group. BMD may be a good alternative medicine for AR patients considering its satisfactory efficacy and better quality of life. 
Acknowledgements
The researchers gratefully acknowledge the financial support provided by the Beijing Natural Science Foundation and the National Natural Science Foundation. The funding agencies had no role in the development of the study design, data collection, or preparing the manuscript for publication.
Authors' contributions JW designed the study, and JZ drafted the paper. HZ and HL made critical revisions. XY and JH were responsible for the statistical analysis of the trial and wrote portions of the statistical methods. JG and SH participated in the study as clinical research associates and revised the paper. All authors read and approved the final paper.
Funding
This trial was supported by funding from the Beijing Natural Science Foundation (grant 7162081) and the National Natural Science Foundation (grant 81674034).
Availability of data and materials
The supporting data are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study design and protocol were approved by the ethics committee of BJHTCM, which is affiliated to Capital Medical University (code 2016BL-047). 
